[go: up one dir, main page]

AR002718A1 - Acidos hidroxamicos que contienen lactamas y composicion farmaceutica con los mismos. - Google Patents

Acidos hidroxamicos que contienen lactamas y composicion farmaceutica con los mismos.

Info

Publication number
AR002718A1
AR002718A1 ARP960101859A AR10185996A AR002718A1 AR 002718 A1 AR002718 A1 AR 002718A1 AR P960101859 A ARP960101859 A AR P960101859A AR 10185996 A AR10185996 A AR 10185996A AR 002718 A1 AR002718 A1 AR 002718A1
Authority
AR
Argentina
Prior art keywords
chain
compounds
same
pharmaceutical composition
mmps
Prior art date
Application number
ARP960101859A
Other languages
English (en)
Inventor
Biswanath De
Menyen Cheng
Michael George Natchus
Christopher Thomas Wahl
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR002718A1 publication Critical patent/AR002718A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos que exhiben una cantidad inhibitoria contra las metaloproteasas de matriz (MMPs). Debido a que sesabe que MMPs juegan un rol en la degradación del tejido, los compuestos de la presente invenciónpueden ser útiles para prevenir o tratar enfermedadesque una actividad MMP excesiva. En particular los compuestos tienen una estructura de acuerdo con la fórmula (I), donde R1, R2, R3 y R4 son variossustituyentes como se describe en la especificación; y Q es una cadena alquil, una cadena alquenil, una cadena heteroalquil o una cadena heteroalquenil, dondedicha cadena tiene 2, 3 ó 4 átomos de carbono y es sustituida o nó sustituido con una o más mitades alquilos; o una sal farmacéuticamente aceptable, oalcoxiamida biohidrolizable, aciloxiamida,o sus imidas. Son preferidos aquellos compuestos donde Q es una cadena alquila que tiene 2, 3 ó 4 átomos de carbono.La invención además se refiere a composiciones farmacéuticas que comprenden estos compuestos.
ARP960101859A 1995-03-21 1996-03-21 Acidos hidroxamicos que contienen lactamas y composicion farmaceutica con los mismos. AR002718A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/407,839 US5672598A (en) 1995-03-21 1995-03-21 Lactam-containing hydroxamic acids

Publications (1)

Publication Number Publication Date
AR002718A1 true AR002718A1 (es) 1998-04-29

Family

ID=23613737

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101859A AR002718A1 (es) 1995-03-21 1996-03-21 Acidos hidroxamicos que contienen lactamas y composicion farmaceutica con los mismos.

Country Status (17)

Country Link
US (1) US5672598A (es)
EP (1) EP0815084B1 (es)
JP (1) JPH11502523A (es)
KR (1) KR19980703151A (es)
AR (1) AR002718A1 (es)
AT (1) ATE248150T1 (es)
AU (1) AU711889B2 (es)
BR (1) BR9607772A (es)
CA (1) CA2216129C (es)
CZ (1) CZ295197A3 (es)
DE (1) DE69629670T2 (es)
HU (1) HUP9800813A3 (es)
IL (1) IL117527A (es)
NO (1) NO974335L (es)
NZ (1) NZ304689A (es)
WO (1) WO1996029313A1 (es)
ZA (1) ZA962253B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL331900A1 (en) * 1996-08-28 1999-08-16 Procter & Gamble 1,4-heterocyclic inhibitors of metaloprotease
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
HUP9904165A3 (en) * 1996-09-19 2002-01-28 Aventis Pharmaceuticals Inc Br 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
PT934259E (pt) * 1996-10-16 2003-01-31 American Cyanamid Co Acidos beta-sulfonamido hidroxamicos como inibidores de metaloproteinases de matriz e de tace
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US20030206874A1 (en) * 1996-11-21 2003-11-06 The Proctor & Gamble Company Promoting whole body health
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en) * 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US20050058709A1 (en) * 1997-06-04 2005-03-17 Fisher Gary J. Methods for inhibiting photoaging of human skin using orally-administered agent
ZA988967B (en) * 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6569636B2 (en) * 1998-05-29 2003-05-27 Hawaii Biotechnology Group, Inc. Assay for modulators of metallo-enzyme activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
AU2003203805B8 (en) * 1998-08-07 2007-02-15 Bristol-Myers Squibb Pharma Company Succinoylamino lactams as inhibitors of ABeta protein production
NZ525513A (en) * 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
EP1129355B1 (en) * 1998-11-12 2005-07-20 Bristol-Myers Squibb Pharma Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
US6737038B1 (en) * 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU778005B2 (en) * 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
WO2000040564A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
DK1150976T3 (da) * 1998-12-31 2003-06-02 Aventis Pharma Inc 3-(Thiosubstituerede amido)lactamer, der er nyttige som inhibitorer af matrixmetalloproteinase
US6262080B1 (en) * 1998-12-31 2001-07-17 Avantis Pharmaceuticals Inc. 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
EP1175405A4 (en) * 1999-02-09 2002-05-15 Bristol Myers Squibb Co LACTAM INHIBITORS OF FACTOR Xa AND ASSOCIATED METHOD
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
US6509330B2 (en) * 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
CA2395862A1 (en) 2000-02-17 2001-08-23 Hong Liu Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production
MXPA02009755A (es) * 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
US6632812B2 (en) 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
JP2004507457A (ja) * 2000-05-11 2004-03-11 協和醗酵工業株式会社 ２−ピペリドン化合物
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
ES2309076T3 (es) * 2000-06-30 2008-12-16 THE PROCTER & GAMBLE COMPANY Composiciones orales que comprenden un agente modulador de la respuesta del huesped.
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
MXPA03000041A (es) * 2000-06-30 2003-10-15 Procter & Gamble Composiciones orales que comprenden agentes microbianos.
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2003033018A1 (en) * 2001-10-18 2003-04-24 Warner-Lambert Company Llc Method for preparing purified matrix metalloproteinase
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
CA2002021A1 (en) * 1988-11-03 1990-05-03 Ann E. Aulabaugh Inhibition of ketol-acid reductoisomerase by oxalylhydroxamate derivatives
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
JPH05502233A (ja) * 1989-12-16 1993-04-22 アストラ・フアーマシユウテイカルズ・リミテツド 薬理学的に活性なアミドカルボキシレート誘導体
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
JPH04217950A (ja) * 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
IL98681A (en) * 1991-06-30 1997-06-10 Yeda Rehovot And Dev Company L Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE4127842A1 (de) * 1991-08-22 1993-02-25 Rhone Poulenc Rorer Gmbh 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
JPH07504184A (ja) * 1992-02-20 1995-05-11 ジェイムズ・ブラック・ファウンデーション・リミテッド コレストシストキニン抑制剤としてのビシクロ［２，２，２］オクタン誘導体
EP0634998B1 (en) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamic acid based collagenase and cytokine inhibitors
EP0639982A1 (en) * 1992-05-01 1995-03-01 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
CN1105799A (zh) * 1993-03-18 1995-07-26 大制药株式会社 作为基质金属蛋白酶抑制剂的喹诺酮衍生物

Also Published As

Publication number Publication date
IL117527A0 (en) 1996-07-23
AU711889B2 (en) 1999-10-21
CA2216129C (en) 2002-08-20
BR9607772A (pt) 1998-07-07
CZ295197A3 (cs) 1998-05-13
MX9707214A (es) 1997-11-29
HUP9800813A3 (en) 1998-09-28
AU5255896A (en) 1996-10-08
DE69629670D1 (de) 2003-10-02
HUP9800813A2 (hu) 1998-07-28
WO1996029313A1 (en) 1996-09-26
EP0815084B1 (en) 2003-08-27
ATE248150T1 (de) 2003-09-15
JPH11502523A (ja) 1999-03-02
CA2216129A1 (en) 1996-09-26
NZ304689A (en) 1999-05-28
NO974335L (no) 1997-11-21
ZA962253B (en) 1996-09-30
US5672598A (en) 1997-09-30
EP0815084A1 (en) 1998-01-07
KR19980703151A (ko) 1998-10-15
NO974335D0 (no) 1997-09-19
DE69629670T2 (de) 2004-06-17
IL117527A (en) 1999-12-22

Similar Documents

Publication Publication Date Title
AR002718A1 (es) Acidos hidroxamicos que contienen lactamas y composicion farmaceutica con los mismos.
NO843836L (no) Terapeutisk aktive sulfamatderivater
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
AR009357A1 (es) Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa
NO308130B1 (no) Arylsylfonamidosubstituerte hydroksaminsyrer som matriksmetalloproteinasehemmere samt anvendelse av samme for fremstilling av medikament
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
IL129068A0 (en) Sulfinic acid derivatives and their preparation and use
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
GEP20033117B (en) Hydroxy Pipecolate Hydroxamic Acid Derivatives as MMP Inhibitors, Pharmaceutical Compositions Containing Them and Their Use for Treatment of Diseases caused by MMP
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
TR200002971T2 (tr) İkameli pirolidin hidroksamat metaloproteaz inhibitörleri
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
ES2163506T3 (es) Derivados de bencimidazolona con actividad dopaminergica central.
IT1251166B (it) Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
BR9712792A (pt) Inibidores de metaloprotease bidentada.
DE69731898D1 (de) Verwendung von Sulphoquinovosyldiacylglycerols zur Behandlung von entzündlichen Hauterkrankungen
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
NZ299727A (en) Preparation of valproic acid analogues and its use for treatment of epilepsy
EA200001029A1 (ru) Производные гигромицина